Arcturus Therapeutics Holdings Inc. Stock
Equities
ARCT
US03969T1097
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.91 USD | +9.15% | +3.45% | -11.48% |
Financials (USD)
Sales 2024 * | 147M | Sales 2025 * | 241M | Capitalization | 689M |
---|---|---|---|---|---|
Net income 2024 * | -68M | Net income 2025 * | 3M | EV / Sales 2024 * | 2.21 x |
Net cash position 2024 * | 364M | Net cash position 2025 * | - | EV / Sales 2025 * | 2.86 x |
P/E ratio 2024 * |
-10.7
x | P/E ratio 2025 * |
-161
x | Employees | 180 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.25% |
Latest transcript on Arcturus Therapeutics Holdings Inc.
1 day | +9.15% | ||
1 week | +3.45% | ||
Current month | +9.15% | ||
1 month | -15.63% | ||
3 months | -19.50% | ||
6 months | +48.69% | ||
Current year | -11.48% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Payne
CEO | Chief Executive Officer | 52 | 13-02-28 |
Andrew Sassine
DFI | Director of Finance/CFO | 59 | 19-08-31 |
Chief Operating Officer | 45 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Edward W. Holmes
BRD | Director/Board Member | 83 | 19-08-31 |
James F. Barlow
BRD | Director/Board Member | 65 | 18-05-26 |
Peter Farrell
CHM | Chairman | 81 | 18-05-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-01 | 27.91 | +9.15% | 939,753 |
24-04-30 | 25.57 | -3.98% | 600,156 |
24-04-29 | 26.63 | +0.30% | 296,545 |
24-04-26 | 26.55 | +1.45% | 275,687 |
24-04-25 | 26.17 | -3.00% | 526,939 |
Delayed Quote Nasdaq, May 01, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.48% | 689M | |
+0.67% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.55% | 24.63B | |
-21.66% | 18.2B | |
+29.96% | 12.01B | |
-1.57% | 11.76B | |
+16.03% | 10.4B | |
-4.80% | 9.94B |
- Stock Market
- Equities
- ARCT Stock